Biomolecules & Therapeutics

  • 제32권1호
  • /
  • Pages.1-12
  • /
  • 2024
  • /
  • 1976-9148(pISSN)
  • /
  • 2005-4483(eISSN)
한국응용약물학회 (The Korean Society of Applied Pharmacology)
권호 표지
DOI QR코드

DOI QR Code

Immunological Mechanisms in Cutaneous Adverse Drug Reactions

  • Ai-Young Lee (Department of Dermatology, Dongguk University Ilsan Hospital)
  • 투고 : 2023.09.22
  • 심사 : 2023.10.23
  • 발행 : 2024.01.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Adverse drug reactions (ADRs) are an inherent aspect of drug use. While approximately 80% of ADRs are predictable, immune system-mediated ADRs, often unpredictable, are a noteworthy subset. Skin-related ADRs, in particular, are frequently unpredictable. However, the wide spectrum of skin manifestations poses a formidable diagnostic challenge. Comprehending the pathomechanisms underlying ADRs is essential for accurate diagnosis and effective management. The skin, being an active immune organ, plays a pivotal role in ADRs, although the precise cutaneous immunological mechanisms remain elusive. Fortunately, clinical manifestations of skin-related ADRs, irrespective of their severity, are frequently rooted in immunological processes. A comprehensive grasp of ADR morphology can aid in diagnosis. With the continuous development of new pharmaceuticals, it is noteworthy that certain drugs including immune checkpoint inhibitors have gained notoriety for their association with ADRs. This paper offers an overview of immunological mechanisms involved in cutaneous ADRs with a focus on clinical features and frequently implicated drugs.

키워드

참고문헌

  1. Al-Quteimat, O. M. (2016) Phenytoin-induced toxic epidermal necrolysis: review and recommendations. J. Pharmacol. Pharmacother. 7, 127-132. https://doi.org/10.4103/0976-500X.189662
  2. Anci, E., Braun, C., Marinosci, A., Rodieux, F., Midun, E., Torres, M. J. and Caubet, J. C. (2021) Viral infections and cutaneous drug-related eruptions. Front. Pharmacol. 11, 586407.
  3. Ariza, A., Mayorga, C., Fernandez, T. D., Barbero, N., Martin-Serrano, A., Perez-Sala, D., Sanchez-Gomez, F. J., Blanca, M., Torres, M. J. and Montanez, M. I. (2015) Hypersensitivity reactions to β-lactams: relevance of hapten-protein conjugates. J. Investig. Allergol. Clin. Immunol. 25, 12-25.
  4. Atanaskovic-Markovic, M., Jankovic, J., Tmusic, V., Gavrovic-Jankulovic, M., Velickovic, T. C., Nikolic, D. and Skoric, D. (2019) Hypersensitivity reactions to antiepileptic drugs in children. Pediatr. Allergy Immunol. 30, 547-552. https://doi.org/10.1111/pai.13055
  5. Aun, M. V., Blanca, M., Garro, L. S., Ribeiro, M. R., Kalil, J., Motta, A. A., Castells, M. and Giavina-Bianchi, P. (2014) Nonsteroidal anti-inflammatory drugs are major causes of drug-induced anaphylaxis. J. Allergy Clin. Immunol. Pract. 2, 414-420. https://doi.org/10.1016/j.jaip.2014.03.014
  6. Ayuso, P., Blanca-Lopez, N., Dona, I., Torres, M. J., Gueant-Rodriguez, R. M., Canto, G., Sanak, M., Mayorga, C., Gueant, J. L., Blanca, M. and Cornejo-Garcia, J. A. (2013) Advanced phenotyping in hypersensitivity drug reactions to NSAIDs. Clin. Exp. Allergy 43, 1097-1109. https://doi.org/10.1111/cea.12140
  7. Babu, K. S. and Belgi, G. (2002) Management of cutaneous drug reactions. Curr. Allergy Asthma Rep. 2, 26-33. https://doi.org/10.1007/s11882-002-0034-x
  8. Balsamo, C., Bono, C. D., Pagano, G., Valastro, V., Ghizzi, C. and Lombardi, F. (2022) Pediatric adverse drug reactions: an observational cohort study after health care workers' training. J. Pediatr. Pharmacol. Ther. 27, 324-329. https://doi.org/10.5863/1551-6776-27.4.324
  9. Bangert, C., Brunner, P. M. and Stingl, G. (2011) Immune functions of the skin. Clin. Dermatol. 29, 360-376.  https://doi.org/10.1016/j.clindermatol.2011.01.006
  10. Barbaud, A. (2009) Skin testing in delayed reactions to drugs. Immunol. Allergy Clin. North Am. 29, 517-535. https://doi.org/10.1016/j.iac.2009.04.010
  11. Bellon, T. (2019) Mechanisms of severe cutaneous adverse reactions: recent advances. Drug Saf. 42, 973-992. https://doi.org/10.1007/s40264-019-00825-2
  12. Beutier, H., Hechler, B., Godon, O., Wang, Y., Gillis, C. M., de Chaisemartin, L., Gouel-Cheron, A., Magnenat, S., Macdonald, L. E., Murphy, A. J., NASA study group, Chollet-Martin, S., Longrois, D., Gachet, C., Bruhns, P. and Jonsson, F. (2018) Platelets expressing IgG receptor FcγRIIA/CD32A determine the severity of experimental anaphylaxis. Sci. Immunol. 3, eaan5997.
  13. Bhardwaj, M., Chiu, M. N. and Sah, S. P. (2022) Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance. Cutan. Ocul. Toxicol. 41, 73-90. https://doi.org/10.1080/15569527.2022.2034842
  14. Bigby, M., Stern, R. S. and Arndt, K. A. (1989) Allergic cutaneous reactions to drugs. Prim. Care 16, 713-727. https://doi.org/10.1016/S0095-4543(21)01338-5
  15. Blanca-Lopez, N., Barrionuevo, E., Andreu, I. and Canto, M. G. (2014) Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs: from phenotyping to genotyping. Curr. Opin. Allergy Clin. Immunol. 14, 271-277. https://doi.org/10.1097/ACI.0000000000000077
  16. Blanca-Lopez, N., Cornejo-Garcia, J. A., Perez-Alzate, D., Perez-Sanchez, N., Plaza-Seron, M. C., Dona, I., Torres, M. J., Canto, G., Kidon, M., Perkins, J. R. and Blanca, M. (2015) Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs in children and adolescents: selective reactions. J. Investig. Allergol. Clin. Immunol. 25, 385-395.
  17. Blaszczyk, B., Lason, W. and Czuczwar, S. J. (2015) Antiepileptic drugs and adverse skin reactions: an update. Pharmacol. Rep. 67, 426-434. https://doi.org/10.1016/j.pharep.2014.11.009
  18. Brockow, K. and Romano, A. (2008) Skin tests in the diagnosis of drug hypersensitivity reactions. Curr. Pharm. Des. 14, 2778-2791. https://doi.org/10.2174/138161208786369821
  19. Chen, C. B., Abe, R., Pan, R. Y., Wang, C. W., Hung, S. I., Tsai, Y. G. and Chung, W. H. (2018) An updated review of the molecular mechanisms in drug hypersensitivity. J. Immunol. Res. 2018, 6431694.
  20. Chen, C. B., Wang, C. W. and Chung, W. H. (2022a) Stevens-Johnson syndrome and toxic epidermal necrolysis in the era of systems medicine. Methods Mol. Biol. 2486, 37-54. https://doi.org/10.1007/978-1-0716-2265-0_3
  21. Chen, C. H., Yu, H. S. and Yu, S. (2022b) cutaneous adverse events associated with immune checkpoint inhibitors: a review article. Curr. Oncol. 29, 2871-2886. https://doi.org/10.3390/curroncol29040234
  22. Chimbetete, T., Buck, C., Choshi, P., Selim, R., Pedretti, S., Divito, S. J., Phillips, E. J., Lehloenya, R. and Peter, J. (2023) HIV-associated immune dysregulation in the skin: a crucible for exaggerated inflammation and hypersensitivity. J. Invest. Dermatol. 143, 362-373. https://doi.org/10.1016/j.jid.2022.07.035
  23. Christiansen, C., Pichler, W. J. and Skotland, T. (2000) Delayed allergy-like reactions to X-ray contrast media: mechanistic considerations. Eur. Radiol. 10, 1965-1975. https://doi.org/10.1007/s003300000543
  24. Clavenna, A. and Bonati, M. (2009) Adverse drug reactions in childhood: a review of prospective studies and safety alerts. Arch. Dis. Child. 94, 724-728. https://doi.org/10.1136/adc.2008.154377
  25. Copaescu, A. M., Ben-Shoshan, M. and Trubiano, J. A. (2022) Tools to improve the diagnosis and management of T-cell mediated adverse drug reactions. Front. Med. (Lausanne) 9, 923991.
  26. de Filippis, R., Soldevila-Matias, P., De Fazio, P., Guinart, D., Fuentes-Dura, I., Rubio, J. M. and Kane, J. M. and Schoretsanitis, G. (2020) Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review. Expert Rev. Clin. Pharmacol. 13, 875-883. https://doi.org/10.1080/17512433.2020.1787831
  27. Del Pozzo-Magana, B. R. and Liy-Wong, C. (2022) Drugs and the skin: a concise review of cutaneous adverse drug reactions. Br. J. Clin. Pharmacol. doi: 10.1111/bcp.15490 [Online ahead of print].
  28. Dispenza, M. C. (2019) Classification of hypersensitivity reactions. Allergy Asthma Proc. 40, 470-473. https://doi.org/10.2500/aap.2019.40.4274
  29. Dona, I., Perez-Sanchez, N., Eguiluz-Gracia, I., Munoz-Cano, R., Bartra, J., Torres, M. J. and Cornejo-Garcia, J. A. (2020) Progress in understanding hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Allergy 75, 561-575. https://doi.org/10.1111/all.14032
  30. Fernandez-Santamaria, R., Palomares, F., Salas, M., Dona, I., Bogas, G., Ariza, A., Rodriguez-Nogales, A., Plaza-Seron, M. C., Mayorga, C., Torres, M. J. and Fernandez, T. D. (2019) Expression of the Tim3-galectin-9 axis is altered in drug-induced maculopapular exanthema. Allergy 74, 1769-1779. https://doi.org/10.1111/all.13847
  31. Fernandez, T. D., Mayorga, C., Salas, M., Barrionuevo, E., Posadas, T., Ariza, A., Laguna, J. J., Moreno, E., Torres, M. J., Dona, I. and Montanez, M. I. (2017) Evolution of diagnostic approaches in beta-lactam hypersensitivity. Expert Rev. Clin. Pharmacol. 10, 671-683. https://doi.org/10.1080/17512433.2017.1313110
  32. Gault, A., Anderson, A. E., Plummer, R., Stewart, C., Pratt, A. G. and Rajan, N. (2021) Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors. Br. J. Dermatol. 185, 263-271. https://doi.org/10.1111/bjd.19750
  33. Geisler, A. N., Phillips, G. S., Barrios, D. M., Wu, J., Leung, D. Y. M., Moy, A. P., Kern, J. A. and Lacouture, M. E. (2020) Immune checkpoint inhibitor-related dermatologic adverse events. J. Am. Acad. Dermatol. 83, 1255-1268. https://doi.org/10.1016/j.jaad.2020.03.132
  34. Goh, S. J. R., Tuomisto, J. E. E., Purcell, A. W., Mifsud, N. A. and Illing, P. T. (2021) The complexity of T cell-mediated penicillin hypersensitivity reactions. Allergy 76, 150-167. https://doi.org/10.1111/all.14355
  35. Gu, C., Wu, L. and Li, X. (2013) IL-17 family: cytokines, receptors and signaling. Cytokine 64, 477-485. https://doi.org/10.1016/j.cyto.2013.07.022
  36. Han, J., Pan, C., Tang, X., Li, Q., Zhu, Y., Zhang, Y. and Liang, A. (2022) Hypersensitivity reactions to small molecule drugs. Front. Immunol. 13, 1016730.
  37. Han, Y., Wang, J. and Xu, B. (2021) Cutaneous adverse events associated with immune checkpoint blockade: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 163, 103376.
  38. Hasegawa, A. and Abe, R. (2020) Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 9, 612.
  39. Heinzerling, L. M., Tomsitz, D. and Anliker, M. D. (2012) Is drug allergy less prevalent than previously assumed? A 5-year analysis. Br. J. Dermatol. 166, 107-114. https://doi.org/10.1111/j.1365-2133.2011.10623.x
  40. Hermans, M. A. W., Otten, R., Karim, A. F. and van Maaren, M. S. (2018) Nonsteroidal anti-inflammatory drug hypersensitivity: not always an allergy! Neth. J. Med. 76, 52-59.
  41. Ho, A. W. and Kupper, T. S. (2019) T cells and the skin: from protective immunity to inflammatory skin disorders. Nat. Rev. Immunol. 19, 490-502. https://doi.org/10.1038/s41577-019-0162-3
  42. Hoigne, R., Lawson, D. H. and Weber, E. (1990) Risk factors for adverse drug reactions--epidemiological approaches. Eur. J. Clin. Pharmacol. 39, 321-325. https://doi.org/10.1007/BF00315403
  43. Hussein, M. R. A. (2016) Drug-induced skin reactions: a pathologist viewpoint. Cutan. Ocul. Toxicol. 35, 67-79. https://doi.org/10.3109/15569527.2015.1015725
  44. Illing, P. T., Purcell, A. W. and McCluskey, J. (2017) The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions. Immunogenetics 69, 617-630. https://doi.org/10.1007/s00251-017-1007-5
  45. Jonsson, F., de Chaisemartin, L., Granger, V., Gouel-Cheron, A., Gillis, C. M., Zhu, Q., Dib, F., Nicaise-Roland, P., Ganneau, C., Hurtado-Nedelec, M., Paugam-Burtz, C., Necib, S., Keita-Meyer, H., Le Dorze, M., Cholley, B., Langeron, O., Jacob, L., Plaud, B., Fischler, M., Sauvan, C., Guinnepain, M. T., Montravers, P., Aubier, M., Bay, S., Neukirch, C., Tubach, F., Longrois, D., Chollet-Martin, S. and Bruhns, P. (2019) An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis. Sci. Transl. Med. 11, eaat1479. https://doi.org/10.1126/scitranslmed.aat1479
  46. Kakeda, M., Schlapbach, C., Danelon, G., Tang, M. M., Cecchinato, V., Yawalkar, N. and Uguccioni, M. (2014) Innate immune cells express IL-17A/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis. Arch. Dermatol. Res. 306, 933-938. https://doi.org/10.1007/s00403-014-1488-0
  47. Khan, D. A., Banerji, A., Bernstein, J. A., Bilgicer, B., Blumenthal, K., Castells, M., Ein, D., Lang, D. M. and Phillips, E. (2019) Cephalosporin allergy: current understanding and future challenges. J. Allergy Clin. Immunol. Pract. 7, 2105-2114. https://doi.org/10.1016/j.jaip.2019.06.001
  48. Kinoshita, M., Ogawa, Y., Hama, N., Ujiie, I., Hasegawa, A., Nakajima, S., Nomura, T., Adachi, J., Sato, T., Koizumi, S., Shimada, S., Fujita, Y., Takahashi, H., Mizukawa, Y., Tomonaga, T., Nagao, K., Abe, R. and Kawamura, T. (2021) Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis. Sci. Transl. Med. 13, eaax2398.
  49. Kuijper, E. C., French, L. E., Tensen, C. P., Vermeer, M. H. and Bouwes Bavinck, J. N. (2020) Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN). J. Eur. Acad. Dermatol. Venereol. 34, 1957-1971. https://doi.org/10.1111/jdv.16339
  50. Kuljanac, I. (2008) Mechanisms of drug hypersensitivity reactions and the skin. Recent Pat. Inflamm. Allergy Drug Discov. 2, 64-71. https://doi.org/10.2174/187221308783399252
  51. Lehloenya, R. J., Peter, J. G., Copascu, A., Trubiano, J. A. and Phillips, E. J. (2020) Delabeling delayed drug hypersensitivity: how far can you safely go? J. Allergy Clin. Immunol. Pract. 8, 2878-2895. https://doi.org/10.1016/j.jaip.2020.07.005
  52. Limsuwan, T. and Demoly, P. (2010) Acute symptoms of drug hypersensitivity (urticaria, angioedema, anaphylaxis, anaphylactic shock). Med. Clin. North Am. 94, 691-710. https://doi.org/10.1016/j.mcna.2010.03.007
  53. Loser, K. and Beissert, S. (2007) Dendritic cells and T cells in the regulation of cutaneous immunity. Adv. Dermatol. 23, 307-333. https://doi.org/10.1016/j.yadr.2007.07.014
  54. Mackay, G. A., Fernandopulle, N. A., Ding, J., McComish, J. and Soeding, P. F. (2021) Antibody or anybody? Considering the role of MRGPRX2 in acute drug-induced anaphylaxis and as a therapeutic target. Front. Immunol. 12, 688930.
  55. Macy, E. (2016) Practical management of patients with a history of immediate hypersensitivity to common non-beta-lactam drugs. Curr. Allergy Asthma Rep. 16, 4.
  56. Mani, R., Monteleone, C., Schalock, P. C., Truong, T., Zhang, X. B. and Wagner, M. L. (2019) Rashes and other hypersensitivity reactions associated with antiepileptic drugs: a review of current literature. Seizure 71, 270-278. https://doi.org/10.1016/j.seizure.2019.07.015
  57. Martin-Serrano, A., Barbero, N., Agundez, J. A., Vida, Y., Perez-Inestrosa, E. and Montanez, M. I. (2016) New advances in the study of IgE drug recognition. Curr. Pharm. Des. 22, 6759-6772.
  58. Montanez, M. I., Mayorga, C., Bogas, G., Barrionuevo, E., Fernandez-Santamaria, R., Martin-Serrano, A., Laguna, J. J., Torres, M. J., Fernandez, T. D. and Dona, I. (2017) Epidemiology, mechanisms, and diagnosis of drug-induced anaphylaxis. Front. Immunol. 8, 614.
  59. Meier-Schiesser, B., Feldmeyer, L., Jankovic, D., Mellett, M., Satoh, T. K., Yerly, D., Navarini, A., Abe, R., Yawalkar, N., Chung, W. H., French, L. E. and Contassot, E. (2019) Culprit drugs induce specific IL-36 overexpression in acute generalized exanthematous pustulosis. J. Invest. Dermatol. 139, 848-858. https://doi.org/10.1016/j.jid.2018.10.023
  60. Min, F., Fan, C., Zeng, Y., He, N., Zeng, T., Qin, B. and Shi, Y. (2022) Carbamazepine-modified HLA-A*24:02-bound peptidome: implication of CORO1A in skin rash. Int. Immunopharmacol. 109, 108804.
  61. Miyagawa, F. and Asada, H. (2021) Current perspective regarding the immunopathogenesis of drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS). Int. J. Mol. Sci. 22, 2147.
  62. Morita, C., Yanase, T., Shiohara, T. and Aoyama, Y. (2018) Aggressive treatment in paediatric or young patients with drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) is associated with future development of type III polyglandular autoimmune syndrome. BMJ Case Rep. 2018, bcr2018225528.
  63. Mota, I., Gaspar, A., Benito-Garcia, F., Correia, M., Chambel, M. and Morais-Almeida, M. (2018) Drug-induced anaphylaxis: seven-year single-center survey. Eur. Ann. Allergy Clin. Immunol. 50, 211-216. https://doi.org/10.23822/EurAnnACI.1764-1489.66
  64. Muntyanu, A., Netchiporouk, E., Gerstein, W., Gniadecki, R. and Litvinov, I. V. (2021) Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management. J. Cutan. Med. Surg. 25, 59-76. https://doi.org/10.1177/1203475420943260
  65. Neuman, M. G., Cohen, L. B. and Nanau, R. M. (2015) Quinolones-induced hypersensitivity reactions. Clin. Biochem. 48, 716-739. https://doi.org/10.1016/j.clinbiochem.2015.04.006
  66. Nguyen, S. M. T., Rupprecht, C. P., Haque, A., Pattanaik, D., Yusin, J. and Krishnaswamy, G. (2021) Mechanisms governing anaphylaxis: inflammatory cells, mediators, endothelial gap junctions and beyond. Int. J. Mol. Sci. 22, 7785.
  67. Nigen, S., Knowles, S. R. and Shear, N. H. (2003) Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J. Drugs Dermatol. 2, 278-299.
  68. Noe, M. H. and Micheletti, R. G. (2020) Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis. Clin. Dermatol. 38, 607-612. https://doi.org/10.1016/j.clindermatol.2020.06.016
  69. Noguera-Morel, L., Hernandez-Martin, A. and Torrelo, A. (2014) Cutaneous drug reactions in the pediatric population. Pediatr. Clin. North Am. 61, 403-426. https://doi.org/10.1016/j.pcl.2013.12.001
  70. Okiyama, N. and Tanaka, R. (2022) Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergol. Int. 71, 169-178. https://doi.org/10.1016/j.alit.2022.01.001
  71. Oscanoa, T. J., Lizaraso, F. and Carvajal, A. (2017) Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur. J. Clin. Pharmacol. 73, 759-770. https://doi.org/10.1007/s00228-017-2225-3
  72. Pach, J. and Leventhal, J. S. (2022) Cutaneous immune-related adverse events secondary to immune checkpoint inhibitors and their management. Crit. Rev. Immunol. 42, 1-20. https://doi.org/10.1615/CritRevImmunol.2023046895
  73. Patel, A. B. and Pacha, O. (2021) Skin reactions to immune checkpoint inhibitors. Adv. Exp. Med. Biol. 1342, 319-330. https://doi.org/10.1007/978-3-030-79308-1_11
  74. Pavlos, R., Mallal, S., Ostrov, D., Buus, S., Metushi, I., Peters, B. and Phillips, E. (2015) T cell-mediated hypersensitivity reactions to drugs. Annu. Rev. Med. 66, 439-454. https://doi.org/10.1146/annurev-med-050913-022745
  75. Perez-Sanchez, N., Dona, I., Bogas, G., Salas, M., Testera, A., Cornejo-Garcia, J. A. and Torres, M. J. (2020) Evaluation of subjects experiencing allergic reactions to non-steroidal anti-inflammatory drugs: clinical characteristics and drugs involved. Front. Pharmacol. 11, 503.
  76. Peter, J. G., Lehloenya, R., Dlamini, S., Risma, K., White, K. D., Konvinse, K. C. and Phillips, E. J. (2017) Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice. J. Allergy Clin. Immunol. Pract. 5, 547-563. https://doi.org/10.1016/j.jaip.2017.01.025
  77. Phillips, E. J., Bigliardi, P., Bircher, A. J., Broyles, A., Chang, Y. S., Chung, W. H., Lehloenya, R., Mockenhaupt, M., Peter, J., Pirmohamed, M., Roujeau, J. C., Shear, N. H., Tanno, L. K., Trubiano, J., Valluzzi, R. and Barbaud, A. (2019) Controversies in drug allergy: testing for delayed reactions. J. Allergy Clin. Immunol. 143, 66-73. https://doi.org/10.1016/j.jaci.2018.10.030
  78. Pichler, W. J. (2019) Immune pathomechanism and classification of drug hypersensitivity. Allergy 74, 1457-1471. https://doi.org/10.1111/all.13765
  79. Pirmohamed, M., Ostrov, D. A. and Park, B. K. (2015) New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. J. Allergy Clin. Immunol. 136, 236-244. https://doi.org/10.1016/j.jaci.2015.06.022
  80. Plachouri, K. M., Vryzaki, E. and Georgiou, S. (2019) Cutaneous adverse events of immune checkpoint inhibitors: a summarized overview. Curr. Drug Saf. 14, 14-20. https://doi.org/10.2174/1574886313666180730114309
  81. Porebski, G., Czarnobilska, E. and Bosak, M. (2015) Cytotoxic‑based assays in delayed drug hypersensitivity reactions induced by antiepileptic drugs. Pol. Arch. Med. Wewn. 125, 823-834.
  82. Quach, H. T., Johnson, D. B., LeBoeuf, N. R., Zwerner, J. P. and Dewan, A. K. (2021) Cutaneous adverse events caused by immune checkpoint inhibitors. J. Am. Acad. Dermatol. 85, 956-966. https://doi.org/10.1016/j.jaad.2020.09.054
  83. Ramirez, G. A., Ripa, M., Burastero, S., Benanti, G., Bagnasco, D., Nannipieri, S., Monardo, R., Ponta, G., Asperti, C., Cilona, M. B., Castagna, A., Dagna, L. and Yacoub, M. R. (2023) Drug reaction with eosinophilia and systemic symptoms (DRESS): focus on the pathophysiological and diagnostic role of viruses. Microorganisms 11, 346.
  84. Redwood, A. J., Pavlos, R. K., White, K. D. andPhillips, E. J. (2018) HLAs: key regulators of T-cell-mediated drug hypersensitivity. HLA 91, 3-16. https://doi.org/10.1111/tan.13183
  85. Rodilla, E. M., Gonzalez, I. D., Yges, E. L., Munoz Bellido, F. J., Gracia Bara, M. T. and Toledano, F. L. (2010) Immunological aspects of nonimmediate reactions to beta-lactam antibiotics. Expert Rev. Clin. Immunol. 6, 789-800. https://doi.org/10.1586/eci.10.53
  86. Romano, A., Valluzzi, R. L., Caruso, C., Maggioletti, M. and Gaeta, F. (2017) Non-immediate cutaneous reactions to beta-lactams: approach to diagnosis. Curr. Allergy Asthma Rep. 17, 23.
  87. Roujeau, J. C. (2006) Immune mechanisms in drug allergy. Allergol. Int. 55, 27-33. https://doi.org/10.2332/allergolint.55.27
  88. Rozieres, A., Vocanson, M., Said, B. B., Nosbaum, A. and Nicolas, J. F. (2009) Role of T cells in nonimmediate allergic drug reactions. Curr. Opin. Allergy Clin. Immunol. 9, 305-310. https://doi.org/10.1097/ACI.0b013e32832d565c
  89. Saeed, H. N. and Chodosh, J. (2016) Immunologic mediators in Stevens-Johnson syndrome and toxic epidermal necrolysis. Semin. Ophthalmol. 31, 85-90. https://doi.org/10.3109/08820538.2015.1115255
  90. Santos Andrade, P. H., da Silva Santos, A., Santos Souza, C. A., Fraga Lobo, I. M. and da Silva, W. B. (2017) Risk factors for adverse drug reactions in pediatric inpatients: a systematic review. Ther. Adv. Drug Saf. 8, 199-210. https://doi.org/10.1177/2042098617702615
  91. Schettini, N., Corazza, M., Schenetti, C., Pacetti, L. and Borghi, A. (2023) Urticaria: a narrative overview of differential diagnosis. Biomedicines 11, 1096.
  92. Seervai, R. N. H., Sinha, A. and Kulkarni, R. P. (2022) Mechanisms of dermatological toxicities to immune checkpoint inhibitor cancer therapies. Clin. Exp. Dermatol. 47, 1928-1942. https://doi.org/10.1111/ced.15332
  93. Senra, L., Mylonas, A., Kavanagh, R. D., Fallon, P. G., Conrad, C., Borowczyk-Michalowska, J., Wrobel, L. J., Kaya, G., Yawalkar, N., Boehncke, W. H. and Brembilla, N. C. (2019) IL-17E (IL-25) enhances innate immune responses during skin inflammation. J. Invest. Dermatol. 139, 1732-1742. https://doi.org/10.1016/j.jid.2019.01.021
  94. Sharma, A., Saito, Y., Hung, S. I., Naisbitt, D., Uetrecht, J. and Bussiere, J. (2019) The skin as a metabolic and immune-competent organ: Implications for drug-induced skin rash. J. Immunotoxicol. 16, 1-12. https://doi.org/10.1080/1547691X.2018.1514444
  95. Shen, M., Er Lim, J. M., Chia, C. and Ren, E. C. (2020) CD39+ regulatory T cells modulate the immune response to carbamazepine in HLA-B*15:02HLA-B*15:02 carriers. Immunobiology 225, 151868.
  96. Shiohara, T. and Mizukawa, Y. (2019) Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. Allergol. Int. 68, 301-308. https://doi.org/10.1016/j.alit.2019.03.006
  97. Sibaud, V., Meyer, N., Lamant, L., Vigarios, E., Mazieres, J. and Delord, J. P. (2016) Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr. Opin. Oncol. 28, 254-263. https://doi.org/10.1097/CCO.0000000000000290
  98. Spoerl, D., Nigolian, H., Czarnetzki, C. and Harr, T. (2017) Reclassifying anaphylaxis to neuromuscular blocking agents based on the presumed patho-mechanism: IgE-mediated, pharmacological adverse reaction or "innate hypersensitivity"? Int. J. Mol. Sci. 18, 1223.
  99. Stevens, W., Buchheit, K. and Cahill, K. N. (2015) Aspirin-exacerbated diseases: advances in asthma with nasal polyposis, urticaria, angioedema, and anaphylaxis. Curr. Allergy Asthma Rep. 15, 69.
  100. Sueki, H., Watanabe, Y., Sugiyama, S. and Mizukawa, Y. (2022) Drug allergy and non-HIV immune reconstitution inflammatory syndrome. Allergol. Int. 71, 185-192. https://doi.org/10.1016/j.alit.2021.12.002
  101. Szatkowski, J. and Schwartz, R. A. (2015) Acute generalized exanthematous pustulosis (AGEP): a review and update. J. Am. Acad. Dermatol. 73, 843-848. https://doi.org/10.1016/j.jaad.2015.07.017
  102. Torres, M. J., Mayorga, C. and Blanca, M. (2009) Nonimmediate allergic reactions induced by drugs: pathogenesis and diagnostic tests. J. Investig. Allergol. Clin. Immunol. 19, 80-90.
  103. Torres, M. J., Barrionuevo, E., Kowalski, M. and Blanca, M. (2014a) Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Immunol. Allergy Clin. North Am. 34, 507-524. https://doi.org/10.1016/j.iac.2014.04.001
  104. Torres, M. J., Mayorga, C., Blanca-Lopez, N. and Blanca, M. (2014b) Hypersensitivity reactions to beta-lactams. Exp. Suppl. 104, 165-184. https://doi.org/10.1007/978-3-0348-0726-5_11
  105. Ushigome, Y., Mizukawa, Y., Kimishima, M., Yamazaki, Y., Takahashi, R., Kano, Y. and Shiohara, T. (2018) Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions. Clin. Exp. Allergy, 48, 1453-1463. https://doi.org/10.1111/cea.13252
  106. Vane, J. R. and Botting, R. M. (2003) The mechanism of action of aspirin. Thromb. Res. 110, 255-258. https://doi.org/10.1016/S0049-3848(03)00379-7
  107. Vocanson, M., Naisbitt, D. J. and Nicolas, J. F. (2020) Current perspective of the etiopathogenesis of delayed-type, and T-cell-mediated drug-related skin diseases. J. Allergy Clin. Immunol. 145, 1142-1144. https://doi.org/10.1016/j.jaci.2020.01.030
  108. Wang, C. W., Yang, L. Y., Chen, C. B., Ho, H. C., Hung, S. I., Yang, C. H., Chang, C. J., Su, S. C., Hui, R. C., Chin, S. W., Huang, L. F., Lin, Y. Y., Chang, W. Y., Fan, W. L., Yang, C. Y., Ho, J. C., Chang, Y. C., Lu, C. W. and Chung, W. H.; the Taiwan Severe Cutaneous Adverse Reaction (TSCAR) Consortium (2018) Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J. Clin. Invest. 128, 985-996. https://doi.org/10.1172/JCI93349
  109. Wang, F., Zhao, Y. K., Li, M., Zhu, Z. and Zhang, X. (2017) Trends in culprit drugs and clinical entities in cutaneous adverse drug reactions: a retrospective study. Cutan. Ocul. Toxicol. 36, 370-376. https://doi.org/10.1080/15569527.2017.1301947
  110. Wang, X., Xiong, J., Xu, W. H., Yu, S., Huang, X., Zhang, J., Tian, C., Huang, D., Jia, W. and Lang, S. (2015) Risk of a lamotrigine-related skin rash: current meta-analysis and postmarketing cohort analysis. Seizure 25, 52-61. https://doi.org/10.1016/j.seizure.2014.12.001
  111. Watanabe, T. and Yamaguchi, Y. (2023) Cutaneous manifestations associated with immune checkpoint inhibitors. Front. Immunol. 14, 1071983.
  112. Wei, B. M., Fox, L. P., Kaffenberger, B. H., Korman, A. M., Micheletti, R. G., Mostaghimi, A., Noe, M. H., Rosenbach, M., Shinkai, K., Kwah, J. H., Phillips, E. J., Bolognia, J. L., Damsky, W. and Nelson, C. A. (2023) Drug-induced hypersensitivity syndrome / drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis. J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2023.02.072 [Online ahead of print].
  113. White, K. D., Chung, W. H., Hung, S. I., Mallal, S. and Phillips, E. J. (2015) Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response. J. Allergy Clin. Immunol. 136, 219-234. https://doi.org/10.1016/j.jaci.2015.05.050
  114. Wilkerson, R. G. (2022) Drug hypersensitivity reactions. Emerg. Med. Clin. North Am. 40, 39-55. https://doi.org/10.1016/j.emc.2021.09.001
  115. Wuillemin, N., Ballmer-Weber, B., Schlapbach, C., Jorg, L. and Yerly, D. (2022) The activation pattern of drug-reacting T cells has an impact on the clinical picture of hypersensitivity reactions. Front. Allergy 3, 804605.
  116. Yamamoto, T. (2022) Skin manifestation induced by immune checkpoint inhibitors. Clin. Cosmet. Investig. Dermatol. 15, 829-841. https://doi.org/10.2147/CCID.S364243
  117. Yazicioglu, M. (2014) Approach to drug allergies in the childhood. Turk Pediatri Ars. 49, 99-103. https://doi.org/10.5152/tpa.2014.1944
  118. Ye, Y. M., Hur, G. Y., Kim, S. H., Ban, G. Y., Jee, Y. K., Naisbitt, D. J., Park, H. S. and Kim, S. H. (2017) Drug-specific CD4+ T-cell immune responses are responsible for antituberculosis drug-induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome. Br. J. Dermatol. 176, 378-386. https://doi.org/10.1111/bjd.14839
  119. Zalewska-Janowska, A., Spiewak, R. and Kowalski, M. L. (2017) Cutaneous manifestation of drug allergy and hypersensitivity. Immunol. Allergy Clin. North Am. 37, 165-181. https://doi.org/10.1016/j.iac.2016.08.006
  120. Zazzara, M. B., Palmer, K., Vetrano, D. L., Carfi, A. and Onder, G. (2021) Adverse drug reactions in older adults: a narrative review of the literature. Eur. Geriatr. Med. 12, 463-473. https://doi.org/10.1007/s41999-021-00481-9
  121. Zhang, C., Van, D. N., Hieu, C. and Craig, T. (2019) Drug-induced severe cutaneous adverse reactions: determine the cause and prevention. Ann. Allergy Asthma Immunol. 123, 483-487. https://doi.org/10.1016/j.anai.2019.08.004
  122. Zhu, H. and Ren, V. (2023) Immunopathogenic insights on preferential human herpesvirus-6 reactivation in drug rash with eosinophilia and systemic symptoms: a scoping review. J. Cutan. Med. Surg. 27, 388-398. https://doi.org/10.1177/12034754231177590
  123. Zhu, L. J., Liu, A. Y., Wong, P. H. and Arroyo, A. C. (2022) Road less traveled: drug hypersensitivity to fluoroquinolones, vancomycin, tetracyclines, and macrolides. Clin. Rev. Allergy Immunol. 62, 505-518. https://doi.org/10.1007/s12016-021-08919-5